US 12,083,228 B2
Methods and compositions for treating respiratory disease
Gale Smith, Germantown, MD (US); Ye Liu, Clarksville, MD (US); Jing-Hui Tian, Germantown, MD (US); Michael J. Massare, Mt. Airy, MD (US); Sarathi Boddapati, Germantown, MD (US); Gregory Glenn, Poolesville, MD (US); Louis Fries, Ellicott City, MD (US); and Iksung Cho, Potomac, MD (US)
Appl. No. 16/629,859
Filed by NOVAVAX, INC., Gaithersburg, MD (US)
PCT Filed Jul. 24, 2018, PCT No. PCT/US2018/043431
§ 371(c)(1), (2) Date Mar. 29, 2021,
PCT Pub. No. WO2019/023196, PCT Pub. Date Jan. 31, 2019.
Claims priority of provisional application 62/536,235, filed on Jul. 24, 2017.
Prior Publication US 2021/0137845 A1, May 13, 2021
Int. Cl. A61K 9/51 (2006.01); A61K 39/155 (2006.01); A61P 11/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 9/5123 (2013.01) [A61K 39/155 (2013.01); A61P 11/00 (2018.01); A61P 31/14 (2018.01); C12N 2760/16022 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01)] 18 Claims
 
1. A method of reducing exacerbations of chronic obstructive pulmonary disease (COPD) in a human subject comprising administering a nanoparticle vaccine to the subject, wherein the nanoparticle comprises: a non-ionic detergent core and a viral glycoprotein, wherein the viral glycoprotein is associated with the core and the detergent is present at about 0.03% to about 0.05%, wherein the viral glycoprotein is an RSV F protein.